BDBM224213 5-{6-(3- chlorophenyl)-7- [(trans-4- methylcyclohexyl) methyl]-8-[(2s,3r)-2- methyl-3- phenylmorpholin-4- yl]-7h-purin-2-yl}- 1,3,4-oxadiazol- 2(3h)-one::US9540377, 16.132

SMILES C[C@@H]1OCCN(c2nc3nc(-c4n[nH]c(=O)o4)nc(-c4cccc(Cl)c4)c3n2C[C@H]2CC[C@H](C)CC2)[C@@H]1c1ccccc1

InChI Key InChIKey=UXFYSVQWWYMTNL-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224213   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224213BDBM224213(US9540377, 16.132 | 5-{6-(3- chlorophenyl)-7- [(tr...)
Affinity DataIC50: 89.5nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent